Toggle Offcanvas
...
 
Immunosuppressive Agents Bids and RFPs

Immunosuppressive Agents Bids and RFPs

Latest Immunosuppressive Agents RFPs, bids and solicitations. Bid on readily available Immunosuppressive Agents contracts with the best and most comprehensive government procurement platform, since 2002.

Bidding for Immunosuppressive Agents RFPs is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Immunosuppressive Agents.

Global Tenders stands out as the largest platform dedicated to bids and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Bids/Contracts/Solicitations Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to bid information, we offer in-depth Immunosuppressive Agents market research, procurement analysis, historical archives, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Immunosuppressive Agents rfps, advanced search filters, market analysis, industry trends, bid training and 24/7 customer support.

18 Live Notices for Immunosuppressive Agents Bids and RFPs

Showing 1 to 18

Selective Immunosuppressants - Tofacitinib Ii.
country Czech Republic
posting date12 Dec 2024
deadline15 Jan 2025
Ozanimod-Containing Medicinal Products
country Czech Republic
posting date11 Dec 2024
deadline13 Jan 2025
Selective Immunosuppressants - Basiliximab
country Czech Republic
posting date10 Dec 2024
deadline09 Jan 2025
Supplies Of Medicinal Products With The Active Substance Vedolizumab 2024
country Czech Republic
posting date09 Dec 2024
deadline09 Jan 2025
Selective Immunosuppressants - Basiliximab
country Czech Republic
posting date09 Dec 2024
deadline09 Jan 2025
Drug Supplies – Active Ingredient Adalimumab – Atc L04Ab04
country Czech Republic
posting date05 Dec 2024
deadline07 Jan 2025
Si - Ozanimod I.
country Czech Republic
posting date04 Dec 2024
deadline08 Jan 2025
Selective Immunosuppressants - Ozanimod I.
country Czech Republic
posting date04 Dec 2024
deadline08 Jan 2025
Lp With The Content Of Vismodegib 2024
country Czech Republic
posting date03 Dec 2024
deadline06 Jan 2025
Supplies Of Medicinal Products For Drug Programs And Various Drugs
country Poland
posting date28 Nov 2024
deadline30 Dec 2024
Purchase And Successive Delivery Of Medicinal Products For Drug And Chemotherapy Programs
country Poland
posting date22 Nov 2024
deadline23 Dec 2024
Supplies Of Medicinal Products For Drug Programs And Various Drugs
country Poland
posting date20 Nov 2024
deadline24 Dec 2024
The Medicine Ravulizumab
country Lithuania
posting date15 Oct 2024
deadline15 Oct 2025
Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Drugs With The Active Ingredient Abatacept (Atc Code: L04Aa24).
country Germany
posting date10 Nov 2023
deadline27 Oct 2025
Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Drugs With The Active Ingredient Certolizumab Pegol (Atc Code: L04Ab05).
country Germany
posting date22 Sep 2023
deadline27 Aug 2025
Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Drugs With The Active Ingredient Tocilizumab (Atc Code: L04Ac07).
country Germany
posting date22 Sep 2023
deadline27 Aug 2025
Conclusion Of A Non-Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For Medicinal Products With The Active Ingredient Fingolimod (Atc Code: L04Aa27).
country Germany
posting date14 Aug 2023
deadline28 Jul 2025
Conclusion Of A Non-Exclusive Discount Agreement In Accordance With § 130A Paragraph 8 Sgb V For Drugs With The Active Ingredient Infliximab (Atc Code: L04Ab02).
country Germany
posting date09 Jun 2023
deadline27 May 2025

Share Share this page